JP2020530282A - 組換えウリカーゼ酵素 - Google Patents

組換えウリカーゼ酵素 Download PDF

Info

Publication number
JP2020530282A
JP2020530282A JP2020500057A JP2020500057A JP2020530282A JP 2020530282 A JP2020530282 A JP 2020530282A JP 2020500057 A JP2020500057 A JP 2020500057A JP 2020500057 A JP2020500057 A JP 2020500057A JP 2020530282 A JP2020530282 A JP 2020530282A
Authority
JP
Japan
Prior art keywords
uricase
replaced
recombinant
utilis
utilis uricase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020500057A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530282A5 (enExample
Inventor
アディティ アール． デシュパンデ，
アディティ アール． デシュパンデ，
ダニカ グルジック，
ダニカ グルジック，
スリダー ゴヴィンダラジャン，
スリダー ゴヴィンダラジャン，
マーク ウェルチ，
マーク ウェルチ，
Original Assignee
アレナ ファーマシューティカルズ， インコーポレイテッド
アレナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレナ ファーマシューティカルズ， インコーポレイテッド, アレナ ファーマシューティカルズ， インコーポレイテッド filed Critical アレナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2020530282A publication Critical patent/JP2020530282A/ja
Publication of JP2020530282A5 publication Critical patent/JP2020530282A5/ja
Priority to JP2023109386A priority Critical patent/JP2023126877A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048—Uricase (1.7.3.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2020500057A 2017-07-07 2018-07-06 組換えウリカーゼ酵素 Pending JP2020530282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023109386A JP2023126877A (ja) 2017-07-07 2023-07-03 組換えウリカーゼ酵素

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762529726P 2017-07-07 2017-07-07
US62/529,726 2017-07-07
US201862678511P 2018-05-31 2018-05-31
US62/678,511 2018-05-31
PCT/US2018/041015 WO2019010369A1 (en) 2017-07-07 2018-07-06 RECOMBINANT ENZYME URICASE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023109386A Division JP2023126877A (ja) 2017-07-07 2023-07-03 組換えウリカーゼ酵素

Publications (2)

Publication Number Publication Date
JP2020530282A true JP2020530282A (ja) 2020-10-22
JP2020530282A5 JP2020530282A5 (enExample) 2021-08-12

Family

ID=64951239

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020500057A Pending JP2020530282A (ja) 2017-07-07 2018-07-06 組換えウリカーゼ酵素
JP2023109386A Pending JP2023126877A (ja) 2017-07-07 2023-07-03 組換えウリカーゼ酵素

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023109386A Pending JP2023126877A (ja) 2017-07-07 2023-07-03 組換えウリカーゼ酵素

Country Status (8)

Country Link
US (2) US20200308534A1 (enExample)
EP (1) EP3655527A4 (enExample)
JP (2) JP2020530282A (enExample)
CN (1) CN111373034A (enExample)
AU (1) AU2018297309A1 (enExample)
CA (1) CA3069197A1 (enExample)
IL (1) IL271813A (enExample)
WO (1) WO2019010369A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
EP4110283A4 (en) * 2020-02-25 2024-02-28 Synlogic Operating Company, Inc. Recombinant bacteria engineered to treat diseases associated with uric acid and methods of use thereof
KR20230110281A (ko) 2020-11-03 2023-07-21 프로탈릭스 리미티드 변형된 유리카제(uricase) 및 이의 용도
CN114480320B (zh) * 2022-02-28 2024-01-16 复旦大学 重组夜猴尿酸酶及其应用
CN118497162B (zh) * 2024-05-24 2025-05-16 广东少和生物科技有限公司 黑酵母菌尿酸氧化酶及其突变体和应用
CN119876071B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 低免疫原性的高活性人源尿酸氧化酶突变体
CN119876069B (zh) * 2025-03-12 2025-10-21 开平牵牛生化制药有限公司 具有高活性且免疫原性弱化的人源尿酸氧化酶突变体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0956383A (ja) * 1995-08-24 1997-03-04 Kikkoman Corp 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PT1588716E (pt) 1998-08-06 2011-05-25 Mountain View Pharmaceuticals Conjugados de peg-urato oxidase e sua utiliza??o
US6913915B2 (en) 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US20050049166A1 (en) * 2003-08-29 2005-03-03 Huang Tsao-Chin Clare Enzyme-based cleaning composition and method of use
GB0326676D0 (en) * 2003-11-15 2003-12-17 Astrazeneca Ab Protein
CN1980687B (zh) * 2004-02-09 2015-05-13 人类基因科学公司 清蛋白融合蛋白
JP2008506785A (ja) 2004-07-21 2008-03-06 フロリダ大学 リサーチファウンデーション インコーポレイティッド インスリン抵抗性の治療及び予防のための組成物及び方法
JP5033177B2 (ja) 2006-04-12 2012-09-26 サビエント ファーマセウティカルズ インク． 陽イオン界面活性剤によるタンパク質の精製
WO2009120707A1 (en) * 2008-03-24 2009-10-01 Altus Pharmaceuticals Inc. Uricase compositions and methods of use
CN101390969A (zh) * 2008-11-03 2009-03-25 中国人民解放军军事医学科学院生物工程研究所 降低血液中尿酸浓度的药物
CN101875922B (zh) * 2009-04-30 2012-02-22 重庆医科大学 一种重组苛求芽孢杆菌胞内尿酸酶及其聚乙二醇修饰与应用
PL398781A1 (pl) 2009-06-25 2012-11-19 Savient Pharmaceuticals, Inc. Sposoby i zestawy do prognozowania ryzyka wystapienia reakcji na wlew oraz zaniku odpowiedzi której posrednicza przeciwciala poprzez monitorowanie kwasu moczowego w surowicy podczas terapii z zastosowaniem pegylowanej urykazy
CN109706217B (zh) * 2010-02-05 2022-12-09 新英格兰生物实验室公司 高保真性限制性内切核酸酶
CN102586315A (zh) * 2012-02-21 2012-07-18 章泽人 一种低尿酸分泌量益生菌及其制备方法
EP2986720B1 (en) * 2013-04-17 2017-09-06 Council of Scientific & Industrial Research Uricase mutants
CN104342415A (zh) * 2014-07-08 2015-02-11 吉林省金梓源生物科技有限公司 一种重组尿酸酶的制备方法
TW201618773A (zh) * 2014-08-11 2016-06-01 艾森塔製藥公司 Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
CN106554948B (zh) 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
EP4445955A3 (en) 2016-03-11 2025-01-08 Cartesian Therapeutics, Inc. Formulations and doses of pegylated uricase
EP3538135A4 (en) 2016-11-11 2020-07-29 Horizon Pharma Rheumatology LLC POLYTHERAPIES OF PREDNISONE AND URICASE MOLECULES AND THEIR USES
CN110612122A (zh) 2017-03-11 2019-12-24 西莱克塔生物科技公司 与用抗炎剂和包含免疫抑制剂之合成纳米载体进行的组合治疗相关的方法和组合物
CN107308452A (zh) * 2017-05-29 2017-11-03 钟术光 一种稳定生物活性材料的组合物的制备方法
GB201713732D0 (en) * 2017-08-25 2017-10-11 Alta Innovations Ltd Tat expression system
CN109223707B (zh) 2018-09-13 2020-12-08 中国药科大学 一种尿酸酶外用凝胶制剂、其制备方法及用途
CN109846909B (zh) * 2019-01-31 2022-03-22 武汉康复得生物科技股份有限公司 可在肠道中催化尿酸降解的组合物及其制备方法和应用
CA3139550A1 (en) * 2019-05-10 2020-11-19 Peg-Bio Biopharm Co., Ltd. (Chongqing) Polyethylene glycol-modified urate oxidase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0956383A (ja) * 1995-08-24 1997-03-04 Kikkoman Corp 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法

Also Published As

Publication number Publication date
IL271813A (en) 2020-02-27
US10815461B2 (en) 2020-10-27
AU2018297309A1 (en) 2020-01-30
EP3655527A1 (en) 2020-05-27
US20200308534A1 (en) 2020-10-01
WO2019010369A1 (en) 2019-01-10
JP2023126877A (ja) 2023-09-12
CA3069197A1 (en) 2019-01-10
US20200071681A1 (en) 2020-03-05
EP3655527A4 (en) 2021-06-16
CN111373034A (zh) 2020-07-03

Similar Documents

Publication Publication Date Title
JP2023126877A (ja) 組換えウリカーゼ酵素
KR102076348B1 (ko) 사람 아르기나제 및 부위-지향성 페길화된 사람 아르기나제 및 그의 용도
JP2022537570A (ja) がんを処置する方法
RU2678124C2 (ru) Бета-лактамазы с улучшенными свойствами для лечения
JP7685309B2 (ja) 組織石灰化の治療方法
CN110078814A (zh) 修饰的fgf-21多肽及其用途
CN111499725A (zh) 结合IL-4受体α的泪脂质运载蛋白突变蛋白
AU2007347695A1 (en) Crystallized oxalate decarboxylase and methods of use
WO2019246317A1 (en) Treatment of a disease or condition in a tissue originating from the endoderm
JP2024023297A (ja) 可溶化アピラーゼ、方法及び使用
JP2023548207A (ja) 尿酸オキシダーゼ製剤及びその応用
Zhang et al. Soluble expression and purification of recombinant bovine ferritin H-chain
CN114507631A (zh) 一种降解尿酸的工程益生菌及其构建方法和应用
CN105693864A (zh) 一种三聚体trail蛋白及其应用
TW202521692A (zh) 靶向痤瘡丙酸桿菌之細胞壁水解酶
TW202315886A (zh) 重組靈芝免疫調節蛋白新突變體及其應用
JP5892648B2 (ja) Ｄｄｓカプセル用タンパク質およびそれを用いた薬剤とその調整方法
CN116888258A (zh) 修饰的红细胞及其治疗高尿酸血症和痛风的用途
CN114569707A (zh) 腺苷脱氨酶或其修饰物在制备糖尿病治疗药物中的应用
CN114480320B (zh) 重组夜猴尿酸酶及其应用
US20240424071A1 (en) Novel mutant of recombinant ganoderma lucidum immunomodulatory protein and use thereof
WO2024088213A1 (en) Combination to induce specific immune tolerance
WO2025002334A1 (zh) 尿酸氧化酶及其聚乙二醇化缀合物的稳定剂及其药物用途
TW201932132A (zh) 藍綠藻生物質於治療b型肝炎病毒感染之用途
US20220378886A1 (en) Methods of treating hyperoxaluria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210705

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220627

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221125

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230703